Vimarsana
Biggest News Aggregation in the World

Orphan Designations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Orphan Designations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Orphan Designations Today - Breaking & Trending Today

Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma - Vimarsana News

Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ -- OS Therapies, a research and clinical-stage biopharmaceutical company and Team Arnav Foundation, a non-profit 501c3 organization focused on...

OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma - Vimarsana News

OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ -- OS Therapies, a research and clinical-stage biopharmaceutical company announced today that the Data Safety & Monitoring Committee (DSMC)...

Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia - Vimarsana News

Ascentage Pharma's Olverembatinib Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Aadi Bioscience Appoints Scott Giacobello as Chief - Vimarsana News

Aadi Bioscience Appoints Scott Giacobello as Chief

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on...

OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma - Vimarsana News

OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma

/PRNewswire/ -- OS Therapies, a research and clinical-stage biopharmaceutical company announced today the dosing of the "First Patient In" for its lead...